Research

Treatment of fibromyalgia syndrome with Super Malic: A randomized, double blind, placebo controlled, crossover pilot study

In a 2005 pilot study, a proprietary tablet (Super Malic) containing 200 mg of malic acid and 50 mg of magnesium was tested as a treatment of primary fibromyalgia syndrome (FM). Twenty-four sequential patients with primary FM were randomized to a fixed dose (3 tablets bid), placebo controlled, 4-week/course, pilot trial followed by a 6-month, open label, dose escalation (up to 6 tablets bid) trial. With dose escalation and a longer duration of treatment in the open label trial (up to six tablets twice a day for six months), significant reductions in the severity of all 3 primary pain/tenderness measures were obtained without limiting risks.  

References:

Russell, I. J., Michalek, J. E., Flechas, J. D., & Abraham, G. E. (1995). Treatment of fibromyalgia syndrome with Super Malic: a randomized, double blind, placebo controlled, crossover pilot study. The Journal of rheumatology, 22(5), 953–958. 

Ingredient in this research

More research on this ingredient

Let’s keep in touch

Don’t worry we only send updates monthly on offers, product changes, and new opportunities for you.